ClinicalTrials.gg
CompletedNCT07492173Updated Mar 25, 2026

Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans

An interventional study of Trifluridine and Tipiracil Tablets and Lonsurf® in Solid Tumor Cancer, sponsored by Shandong New Time Pharmaceutical Co., LTD. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Shandong New Time Pharmaceutical Co., LTD (part of Lunan Pharmaceutical Group) · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Nov 2022, registered Mar 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The test formulation of Trifluridine and Tipiracil Tablets (20 mg) is bioequivalent to the reference formulation (Lonsurf®) in Chinese patients with solid tumors under fed and fasting conditions.

Read the detailed description

This is a multicenter, randomized, open-label, two-drug, single-dose, four-cycle, crossover study aimed at evaluating the bioequivalence of the test formulation versus the reference formulation, trifluorouracil tepiazole tablets (20mg), in Chinese patients with solid tumors. The planned blood sampling time points: 0h (within 1 hour before administration) and 20 minutes, 40 minutes, 1 hour, 1 hour 20 minutes, 1 hour 40 minutes, 2 hours, 2 hours 20 minutes, 2 hours 40 minutes, 3 hours, 3 hours 20 minutes, 3 hours 40 minutes, 4 hours, 4.5 hours, 5 hours, 6 hours, 8 hours, 12 hours, 24 hours, a total of 19 points. Blood sampling time points after the meal: 0h (within 1 hour before administration) and 30 minutes, 1 hour, 1 hour 20 minutes, 1 hour 40 minutes, 2 hours, 2 hours 20 minutes, 2 hours 40 minutes, 3 hours, 3 hours 20 minutes, 3 hours 40 minutes, 4 hours, 4.5 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, a total of 19 points.

02

Conditions studied

  • Solid Tumor Cancer
03

In context

Lead sponsor

Shandong New Time Pharmaceutical Co., LTD is the lead sponsor of 35 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects must meet all of the following inclusion criteria to be enrolled in this study:

  1. Aged 18-70 years (inclusive), male or female;
  2. Patients with solid tumors confirmed by histopathology or cytology;
  3. Expected survival > 3 months;
  4. (ECOG) performance status of 0 or 1;
  5. Able to take oral medication (i.e., not using a feeding tube);
  6. Adequate organ function based on the following laboratory values obtained within 7 days prior to the first dose:

    1. (HB) ≥ 100 g/L;
    2. (ANC) ≥ 1.5 × 10⁹/L;
    3. (PLT) ≥ 80 × 10⁹/L;
    4. Total serum (TBIL) ≤ 1.5 × (ULN);
    5. (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, or ≤ 5 × ULN in the presence of liver ;
    6. (Ccr) ≥ 60 mL/min;
    7. Urine protein \< 2+;
    8. (INR) \< 1.5; activated partial thromboplastin time (APTT) and prothrombin time (PT) ≤ 1.5 × ULN;
    9. Normal or electrocardiogram abnormalities determined by the investigator to be not .

8. Female patients of must have a negative serum pregnancy test within 7 days prior to the first dose and must agree to use adequate and effective during the study until 6 months after discontinuation of the study drug; male patients must agree to use adequate and effective contraception during the study until 6 months after discontinuation of the study drug; 9. Patients voluntarily participate in this study and sign the form, are compliant, and can cooperate with the study observations.

Subjects who meet any of the following exclusion criteria will not be enrolled in this study:

  1. Presence of severe diseases or serious medical conditions (e.g., ileus, gastrointestinal bleeding, intestinal obstruction, pulmonary fibrosis, uncontrolled diabetes (fasting blood glucose (FBG) > 10 mmol/L), renal insufficiency, hepatic insufficiency, mental illness, cerebrovascular disease, ulcers requiring blood transfusion, etc.);
  2. Presence of ascites, pleural effusion, or pericardial effusion requiring drainage within 4 weeks prior to screening;
  3. Occurrence of myocardial infarction, severe/unstable angina pectoris, or symptomatic congestive heart failure of (NYHA) class III or IV within 12 months prior to the first dose;
  4. Any clinically significant abnormality in virus surface antigen, Treponema pallidum specific antibody, antibody, or virus antibody;
  5. Patients with diseases requiring therapy or a history of organ transplantation;
  6. Known or clinical symptoms suggestive of brain metastases;
  7. Presence of active infection (i.e., body temperature ≥ 38°C due to infection);
  8. Any unresolved toxicity of grade 2 or higher from any previous treatment (excluding anemia, alopecia, skin pigmentation, and chemotherapy-induced neurotoxicity);
  9. Receipt of any of the following treatments within the specified time frame prior to screening:

    1. Major surgery within 4 weeks (major surgery: laparotomy, thoracotomy, and visceral resection by laparoscopic surgery);
    2. Any anti-tumor therapy within 2 weeks;
    3. Any drug within 4 weeks;
    4. Blood transfusion within 2 weeks.
  10. Prior history of gastrectomy;
  11. Pregnant or breastfeeding women;
  12. History of allergy to Trifluridine and Tipiracil Tablets or any of their components;
  13. Patients with a history or current presence of severe interstitial pneumonia;
  14. Excessive consumption of tea, coffee, or caffeinated beverages within 3 months prior to screening (more than 8 cups per day, 1 cup = 250 mL), or consumption of any food or beverage containing alcohol, caffeine, or rich in xanthines within 48 hours prior to study drug administration (e.g., coffee, strong tea, chocolate, cola, grapefruit, etc.);
  15. Inability to adhere to a uniform diet, such as intolerance to standard meals, lactose intolerance (e.g., diarrhea after drinking milk), or dysphagia;
  16. Average daily smoking ≥ 5 cigarettes within 3 months prior to screening, or unwillingness to abstain from smoking during the study period;
  17. Alcohol abuse within 3 months prior to screening (consuming more than 14 units of alcohol per week: 1 unit ≈ 285 mL of beer, or 25 mL of spirits, or 100 mL of wine), or unwillingness to abstain from alcohol during the study period, or positive alcohol breath test result (test value > 0 mg/100 mL);
  18. History of drug abuse within the past 5 years or positive urine drug screen;
  19. Difficulty with blood collection, or needle phobia, or hemophobia, or intolerance to venipuncture;
  20. Vaccination within 2 weeks prior to screening or planned during the study period;
  21. Blood donation or other blood loss resulting in total blood loss ≥ 400 mL within 3 months prior to screening (excluding physiological blood loss in females);
  22. Any other condition that the investigator deems inappropriate for participation in this study.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Other
    Fasting

    Drug: Trifluridine and Tipiracil Tablets · Drug: Lonsurf®

  • Other
    Feed

    Drug: Trifluridine and Tipiracil Tablets · Drug: Lonsurf®

Interventions

  • DrugTrifluridine and Tipiracil Tablets

    strength: Trifluridine 20 mg, Tipiracil Hydrochloride 9.420 mg (equivalent to Tipiracil 8.19 mg) (strength abbreviated as 20 mg expressed as Trifluridine), batch number: 304220201, manufacturing date: February 23, 2022, tentative expiry date: January 2024; Manufactured by Shandong New Time Pharmaceutical Co., Ltd. Three tablets each time.

  • DrugLonsurf®

    Trifluridine and Tipiracil Tablets, strength: 20 mg (expressed as Trifluridine), batch number: 0K71, manufacturing date: November 2, 2020, expiry date: November 1, 2023; Manufactured by Taiho Pharmaceutical Co., Ltd. Kitajima Plant. Three tablets each time.

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    Time frame: 24 hours post-dose in each period

  2. Area under the plasma concentration versus time curve (AUC) 0-t

    Time frame: 24 hours post-dose in each period

  3. Area under the plasma concentration versus time curve (AUC)0-∞

    Time frame: 24 hours post-dose in each period]

Secondary outcomes

  1. maximum plasma concentration (tmax)

    Time frame: 24 hours post-dose in each period

  2. elimination rate constant(λz)

    Time frame: 24 hours post-dose in each period

  3. terminal elimination half-life(t1/2)

    Time frame: 24 hours post-dose in each period

  4. Percentage of residual area(AUC_%Extrap)

    Time frame: 24 hours post-dose in each period

07

Study locations

1 site
  • Hunan Cancer Hospital
    Changsha, Hunan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Jun 2023, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 25, 2026
StartActual
Nov 21, 2022
Primary completionActual
Jun 25, 2023
CompletionActual
Jun 25, 2023
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07492173
Responsible party
Sponsor
First posted
Mar 25, 2026
Start date
Nov 21, 2022
Primary completion
Jun 25, 2023
Completion
Jun 25, 2023
Last update
Mar 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion